Bruker 8-K
Leadership change
QIAGEN CEO Thierry L. Bernard joins the Board, expanding it to 12 directors.
Filed 2026-04-01 07:00 ET
- 5.02 Officer/director change
- 9.01 Financial Statements and Exhibits
Summary
Bruker appointed Thierry L. Bernard to its Board, effective 4/1/2026, expanding the Board to 12 directors. He will serve through the 2027 Annual Meeting; his compensation will match that of other non-employee directors. Bernard is QIAGEN’s CEO and plans to step down when a successor is appointed.
Investor Takeaways
- Bruker said it will disclose Bernard’s committee assignments once determined.
The summary is written by an AI model reading the filing.
Model 005 · prompt 01d34d48e3